(19)
(11) EP 2 831 270 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.05.2018 Bulletin 2018/20

(45) Mention of the grant of the patent:
28.03.2018 Bulletin 2018/13

(21) Application number: 13713873.1

(22) Date of filing: 02.04.2013
(51) International Patent Classification (IPC): 
C12Q 1/68(2018.01)
(86) International application number:
PCT/EP2013/056875
(87) International publication number:
WO 2013/144362 (03.10.2013 Gazette 2013/40)

(54)

BIOMARKER FOR BLADDER CANCER

BIOMARKER FÜR BLASENKREBS

BIOMARQUEUR POUR CANCER DE LA VESSIE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 30.03.2012 EP 12162564

(43) Date of publication of application:
04.02.2015 Bulletin 2015/06

(73) Proprietor: Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
52056 Aachen (DE)

(72) Inventors:
  • ROSE, Michael
    52134 Herzogenrath (DE)
  • DAHL, Edgar
    B-4721 Kelmis (BE)

(74) Representative: Kröncke, Rolf et al
Gramm, Lins & Partner Patent- und Rechtsanwälte PartGmbB Freundallee 13 a
30173 Hannover
30173 Hannover (DE)


(56) References cited: : 
WO-A1-2010/102823
   
  • ANTONY P ET AL: "Charakterisierung von DNA-Methylierungs-Biomarkern fà 1/4 r das Harnblasenkarzinom", DER PATHOLOGE ; ORGAN DER DEUTSCHEN ABTEILUNG DER INTERNATIONALEN AKADEMIE FÜR PATHOLOGIE, DER DEUTSCHEN, DER ÖSTERREICHISCHEN UND DER SCHWEIZERISCHEN GESELLSCHAFT FÜR PATHOLOGIE UND DES BERUFSVERBANDES DEUTSCHER PATHOLOGEN, SPRINGER, BERLIN, DE, vol. 31, no. 2, 28 August 2010 (2010-08-28), pages 244-250, XP019843778, ISSN: 1432-1963
  • YOUNG KYOON KIM AND WUN-JAE KIM: "Epigenetic markers as promising prognosticators for bladder cancer", INTERNATIONAL JOURNAL OF UROLOGY, CHURCHILL LIVINGSTONE, TOKYO, JP, vol. 16, 1 January 2009 (2009-01-01), pages 17-22, XP007914275, ISSN: 0919-8172, DOI: 10.1111/J.1442-2042.2008.02143.X [retrieved on 2008-08-20]
  • YUE CHUN-MEI ET AL: "Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma", WORLD JOURNAL OF GASTROENTEROLOGY, WJG PRESS, CN, vol. 9, no. 6, 1 June 2003 (2003-06-01), pages 1174-1178, XP002470631, ISSN: 1007-9327
  • GÖTZE SILKE ET AL: "ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 17 December 2009 (2009-12-17), page 447, XP021067014, ISSN: 1471-2407, DOI: 10.1186/1471-2407-9-447
  • Yan Lu: "Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models", Am J Transl Res, 1 January 2011 (2011-01-01), pages 8-27, XP055028054, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl es/PMC2981423/pdf/ajtr0003-0008.pdf [retrieved on 2012-05-24] cited in the application
  • J VEECK ET AL: "The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation", ONCOGENE, vol. 27, no. 6, 31 January 2008 (2008-01-31), pages 865-876, XP055028055, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1210669 cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).